Michael Whitt

Prof. Michael Whitt

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
KMKathleen M. McAndrews
Kathleen M. McAndrews
DDDara P. Dowlatshahi
Dara P. Dowlatshahi
JDJianli Dai
Jianli Dai
LBLisa M. Becker
Lisa M. Becker
JHJanine Hensel
Janine Hensel
RKRaghu Kalluri
Raghu Kalluri
Evaluation of potential immunity against the novel severe acute respiratory syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health, as well as social and economic recovery. Generation of antibody response to SARS-CoV-2 (seroconversion) may inform on acquired immunity from prior exposure, and antibodies against the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection. Some serology assays rely solely on SARS-CoV-2 nucleocapsid protein (N-protein) as the antibody detection antigen; however, whether such immune responses correlate with S-RBD response and COVID-19 immunity remains unknown. Here, we generated a quantitative serological ELISA using recombinant S-RBD and N-protein for the detection of circulating antibodies in 138 serial serum samples from 30 reverse transcription PCR–confirmed, SARS-CoV-2–hospitalized patients, as well as 464 healthy and non–COVID-19 serum samples that were collected between June 2017 and June 2020. Quantitative detection of IgG antibodies against the 2 different viral proteins showed a moderate correlation. Antibodies against N-protein were detected at a rate of 3.6% in healthy and non–COVID-19 sera collected during the pandemic in 2020, whereas 1.9% of these sera were positive for S-RBD. Approximately 86% of individuals positive for S-RBD–binding antibodies exhibited neutralizing capacity, but only 74% of N-protein–positive individuals exhibited neutralizing capacity. Collectively, our studies show that detection of N-protein–binding antibodies does not always correlate with presence of S-RBD–neutralizing antibodies and caution against the extensive use of N-protein–based serology testing for determination of potential COVID-19 immunity.

13 December 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
Chad MireChad Mire
Chad Mire
KVKrista M Versteeg
Krista M Versteeg
RCRobert W Cross
Robert W Cross
KAKrystle N Agans
Krystle N Agans
KFKarla A. Fenton
Karla A. Fenton
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Nipah virus (NiV) is a highly pathogenic zoonotic agent in the family Paramyxoviridae that is maintained in nature by bats. Outbreaks have occurred in Malaysia, Singapore, India, and Bangladesh and have been associated with 40 to 75% case fatality rates. There are currently no vaccines or postexposure treatments licensed for combating human NiV infection.

15 July 2010 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CMChad E. Mire
Chad E. Mire
JWJudith M. White
Judith M. White
MWMichael Whitt
Michael Whitt
To study VSV entry and the fate of incoming matrix (M) protein during virus uncoating we used recombinant viruses encoding M proteins with a C-terminal tetracysteine tag that could be fluorescently labeled using biarsenical (Lumio) compounds. We found that uncoating occurs early in the endocytic pathway and is inhibited by expression of dominant-negative (DN) Rab5, but is not inhibited by DN-Rab7 or DN-Rab11. Uncoating, as defined by the separation of nucleocapsids from M protein, occurred between 15 and 20 minutes post-entry and did not require microtubules or an intact actin cytoskeleton. Unexpectedly, the bulk of M protein remained associated with endosomal membranes after uncoating and was eventually trafficked to recycling endosomes. Another small, but significant fraction of M distributed to nuclear pore complexes, which was also not dependent on microtubules or polymerized actin. Quantification of fluorescence from high-resolution confocal micrographs indicated that after membrane fusion, M protein diffuses across the endosomal membrane with a concomitant increase in fluorescence from the Lumio label which occurred soon after the release of RNPs into the cytoplasm. These data support a new model for VSV uncoating in which RNPs are released from M which remains bound to the endosomal membrane rather than the dissociation of M protein from RNPs after release of the complex into the cytoplasm following membrane fusion. Vesicular stomatitis virus (VSV) is a prototypic enveloped virus that enters cells following endocytosis and a low pH-dependent membrane fusion event between the viral and endosomal membrane. To initiate a productive infection the viral nucleocapsid must dissociate from the matrix (M) protein, which underlies the viral membrane, in a process known as uncoating. The requirements for VSV uncoating are poorly understood. Here we used a virus containing fluorescent M protein to follow VSV uncoating in live cells. This analysis resulted in three new findings which provide for the first time a description of matrix and nucleocapsid trafficking during VSV uncoating. We found that most of the M protein remains bound to the endosomal membrane after virus-endosome fusion and that the nucleocapsid is released into the cytoplasm where replication occurs. While most of M remains membrane-bound, a small but detectable fraction is released during uncoating and is trafficked to nuclear pores. This has not been previously observed and may aid in shutting down host responses to infection. Collectively we provide the first spatio-temporal description of VSV uncoating by visualizing the uncoating process in live cells.

1 October 2011 in Methods
Verified
Journal Article
Closed access
MWMichael Whitt
Michael Whitt
CMChad E. Mire
Chad E. Mire

1 April 2010 in Journal of Urology
Verified
Journal Article
Closed access
GCGuimin Chang
Guimin Chang
SXShuping Xu
Shuping Xu
MWMakiko Watanabe
Makiko Watanabe
HJHimangi R. Jayakar
Himangi R. Jayakar
MWMichael Whitt
Michael Whitt
JGJeffrey R. Gingrich
Jeffrey R. Gingrich
Vesicular stomatitis virus has been investigated as an oncolytic agent for cancer therapy because it preferentially replicates in tumor but not in normal cells due to the lack of a robust interferon antiviral system in transformed cells. However, wild-type vesicular stomatitis virus can induce a strong systemic immunological response and replicate in the central nervous system, potentially limiting its clinical usefulness. We report the construction of the recombinant, replication restricted vesicular stomatitis virus encoding SV5-F, which can induce syncytial formation with enhanced oncolytic properties against TRAMP-C2 tumors in an immunocompetent mouse model of prostate cancer. We constructed the SV5-F recombinant restricted virus vector by replacing the vesicular stomatitis virus G gene with that of the SV5-F transgene to generate rVSV-DeltaG-SV5-F. Morphological changes and DNA fragmentation induced by rVSV-DeltaG-GFP or rVSV-DeltaG-SV5-F were determined by phase contrast microscopy and gel electrophoresis. In vitro cytotoxicity by recombinant vesicular stomatitis virus was done by MTT assay. In vivo study of rVSV treatment was done in immunocompetent mice by subcutaneous administration of TRAMP-C2 cells. In vitro characterization of the recombinant fusogenic VSV-DeltaG vector on TRAMP-C2 cells showed significantly enhanced apoptotic and cytotoxic effects relative to a similar virus encoding green fluorescent protein, that is rVSV-DeltaG-GFP. Regardless of initial tumor size intratumor rVSV-DeltaG-SV5-F administration in mice bearing subcutaneous TRAMP-C2 tumors resulted in a significantly reduced tumor load over that of the nonfusogenic green fluorescent control virus and of heat inactivated recombinant vesicular stomatitis virus in treated animals (p <0.01). Results show that G complemented recombinant VSV-DeltaG vectors, especially rVSV-DeltaG-SV5-F, are an effective oncolytic agent against mouse prostate cancer cells in vitro and in an in vivo immunocompetent mouse model system.